Neugrastim
Generic Name
neugrastim-300-mcg-injection
Manufacturer
Biocon
Country
India
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| neugrastim 300 mcg injection | ৳ 2,800.00 | N/A |
Description
Overview of the medicine
Neugrastim (Filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of white blood cells (neutrophils) in patients undergoing chemotherapy or bone marrow transplantation, or with severe chronic neutropenia.
Uses & Indications
Dosage
Adults
Chemotherapy-induced neutropenia: 5 mcg/kg/day SC or IV, continuing until ANC >10,000 cells/mm³. Severe chronic neutropenia: 5 mcg/kg/day SC.
Elderly
No specific dose adjustment generally required, but monitor carefully for side effects and efficacy.
Renal_impairment
No specific dose adjustment recommended, but monitor neutrophil counts closely.
How to Take
Administer subcutaneously (SC) or intravenously (IV). For SC administration, the patient or caregiver can be trained to inject. Administer daily until neutrophil count recovers or as directed by physician.
Mechanism of Action
Filgrastim binds to G-CSF receptors on hematopoietic stem cells and progenitor cells, stimulating their proliferation, differentiation, and maturation into neutrophils. It also enhances the functional activity of mature neutrophils.
Pharmacokinetics
Onset
Neutrophil count increase usually within 24 hours.
Excretion
Mainly via renal excretion, with a small amount excreted unchanged in urine.
Half life
Approximately 3.5 hours after subcutaneous administration.
Absorption
Rapidly absorbed after subcutaneous injection, with peak serum concentrations typically occurring within 3-5 hours.
Metabolism
Primarily metabolized by proteolytic degradation in the kidneys and other tissues.
Side Effects
Contraindications
- Hypersensitivity to filgrastim or any components of the product.
- History of severe allergic reactions (e.g., anaphylaxis) to G-CSFs.
Drug Interactions
Lithium
May potentiate the myeloproliferative effects of filgrastim, monitor neutrophil counts closely.
Chemotherapy and Radiation
Do not administer Neugrastim within 24 hours before or after cytotoxic chemotherapy.
Storage
Store refrigerated between 2°C and 8°C (36°F and 46°F). Do not freeze. Protect from light. Do not shake.
Overdose
Overdose effects are generally managed with supportive care. The effects are usually reversible upon discontinuation of therapy.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. It is unknown if filgrastim is excreted in human milk; caution should be exercised when administered to a nursing woman.
Side Effects
Contraindications
- Hypersensitivity to filgrastim or any components of the product.
- History of severe allergic reactions (e.g., anaphylaxis) to G-CSFs.
Drug Interactions
Lithium
May potentiate the myeloproliferative effects of filgrastim, monitor neutrophil counts closely.
Chemotherapy and Radiation
Do not administer Neugrastim within 24 hours before or after cytotoxic chemotherapy.
Storage
Store refrigerated between 2°C and 8°C (36°F and 46°F). Do not freeze. Protect from light. Do not shake.
Overdose
Overdose effects are generally managed with supportive care. The effects are usually reversible upon discontinuation of therapy.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. It is unknown if filgrastim is excreted in human milk; caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months, refer to product packaging for exact expiry.
Availability
Hospitals, Clinics, Specialty Pharmacies
Approval Status
Approved
Patent Status
Off-patent (Filgrastim)
WHO Essential Medicine
YesClinical Trials
Extensive clinical trials have established the efficacy and safety of filgrastim in various neutropenic conditions. Ongoing trials continue for biosimilar approval and new indications.
Lab Monitoring
- Complete Blood Count (CBC) with differential, especially neutrophil counts, regularly (daily during initial treatment).
- Monitor platelet counts.
- Monitor for signs of splenic enlargement (physical examination or imaging if symptoms arise).
Doctor Notes
- Ensure proper patient education on subcutaneous injection technique, storage, and safe disposal of syringes.
- Monitor for signs of splenic enlargement, acute respiratory distress syndrome, and allergic reactions.
- Avoid administration within 24 hours of chemotherapy due to potential myelosuppression exacerbation.
Patient Guidelines
- Report any unusual pain in the upper left abdomen or shoulder tip immediately (may indicate splenic rupture).
- Seek immediate medical attention for any signs of allergic reaction (e.g., rash, hives, difficulty breathing, swelling of face/lips/tongue).
- Do not shake the syringe; shaking may damage the protein.
Missed Dose Advice
If a dose is missed, administer it as soon as remembered. If it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose.
Driving Precautions
Filgrastim is not known to impair the ability to drive or operate machinery. However, fatigue or headache are common side effects, so caution is advised if these occur and affect concentration.
Lifestyle Advice
- Maintain good hydration by drinking plenty of fluids.
- Avoid strenuous physical activity or activities that might lead to abdominal trauma if splenic enlargement is a concern.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.